[ad_1]
The Turkish government announced on Thursday (24) that the preliminary results of the study of Coronavac, the Sinovac vaccine against Covid-19, in the country indicate an efficiency of 91.25%.
Scientists hope that the numbers, already higher than other vaccines with revealed efficacy, such as those from Oxford / AstraZeneca and Sinopharm, will continue to grow, according to the Reuters news agency.
According to the Turkish arm of the BBC, the country’s scientific committee analyzed data from 1,322 people. There were 3 cases of Covid in the 752 vaccinated volunteers and 26 cases of the disease in the 570 who were part of the control group, which received a placebo.
The committee, according to the BBC, reported that 6 cases in the placebo group were severe and required hospitalization.
In the group that received the vaccine, 2 had no symptoms and one only had a runny nose.
Dimas Covas, director of the Butantan Institute, responsible for the tests in Brazil, said during a press conference on Wednesday (23) that there were no serious cases of Covid-19 in Brazil among those who took Coronavac.
The number of volunteers analyzed so far in the Turkish study is considerably less than that found in the Brazilian trials, which number 13,000 people.
In Brazil, the publication of the results of the effectiveness of Coronavac had been scheduled by the government of São Paulo and by the Butantan Institute for Wednesday (23). However, the announcement only said that the vaccine had reached at least the protection threshold required by Anvisa and the WHO, which is 50% effective.
Representatives of the São Paulo government stated that they would not disclose the effectiveness that day because the data had been sent to Sinovac for review.
One of the hypotheses for the need for review is the possibility that different efficacies have been documented in the countries where the immunizer was tested, which would explain the need for data review.
